Virus-like particles (VLPs) provide great potential to develop future vaccines against highly pathogenic viral pathogens. VLPs mimic the virus in structure and morphology, but are non-infectious, featuring a high safety profile. The goal of our proposed project is to develop vaccine technology based on recombinant VLPs. Respiratory syncytial virus (RSV) and influenza virus are important respiratory viral pathogens. There is no licensed vaccine against RSV. There are 9 times more deaths by RSV than those by influenza among young infants. The fact that licensed RSV drugs are based on antibodies highly supports the possibility to develop an effective RSV vaccine. We have developed RSV VLP vaccines that are proven to be effective in preventing RSV enhanced disease from recent feasibility studies. However, RSV VLP vaccine technology is in an early stage of development and much study is needed to provide sufficient preclinical efficacy data of RSV VLP vaccines. We hypothesize that RSV VLP vaccines developed in our feasibility studies will be highly effective in inducing protective immunity against RSV. In the specific aim 1, we will focus on obtaining sufficient proof-of-concept efficacy data of RSV VLP vaccines as well as testing long-term immunity and non-needle delivery technologies (intranasal, microneedle skin, and oral vaccination). As for aim 2, we will develop antigen targeting vaccine adjuvant systems by using molecularly adjuvanted VLP technology and test licensed adjuvants. Also, utilizing VLP vaccine technology, we have developed a promising universal influenza VLP vaccine and obtained sufficient proof-of-concept efficacy data, which is expected to significantly improve the current egg-substrate based influenza vaccines. In the aim 3, we will extend the preclinical efficacy tests of VLP vaccines to cotton rats (RSV VLPs) and ferrets (novel universal influenza VLPs). VLP vaccines proposed in this application will provide an excellent system to prove VLP vaccine technologies which are also applicable to other biodefense pathogens.

Public Health Relevance

Recombinant virus-like particles are considered as a promising new technology to develop future vaccines against viral pathogens such as influenza and Respiratory Syncytial virus, both of which continue to cause public health problems. Therefore, development of virus-like particle vaccine technology including novel adjuvants and non-needle vaccine delivery will have a significant impact on developing new vaccines, and thus improving the public health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI105170-01
Application #
8495582
Study Section
Special Emphasis Panel (ZAI1-SM-M (J1))
Program Officer
Salomon, Rachelle
Project Start
2013-01-15
Project End
2017-12-31
Budget Start
2013-01-15
Budget End
2013-12-31
Support Year
1
Fiscal Year
2013
Total Cost
$838,288
Indirect Cost
$199,524
Name
Georgia State University
Department
Miscellaneous
Type
Organized Research Units
DUNS #
837322494
City
Atlanta
State
GA
Country
United States
Zip Code
30302
Music, Nedzad; Reber, Adrian J; Kim, Min-Chul et al. (2016) Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine 34:466-73
Song, Byung-Min; Kang, Hyun-Mi; Lee, Eun-Kyoung et al. (2016) Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens. Vaccine 34:678-86
Lee, Young-Tae; Kwon, Young-Man; Kang, Sang-Moo (2016) Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus? Nanomedicine (Lond) 11:439-42
Lee, Yu-Na; Lee, Young-Tae; Kim, Min-Chul et al. (2016) A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus. J Immunol 196:2637-45
Lee, Yu-Na; Hwang, Hye Suk; Kim, Min-Chul et al. (2016) Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin. Nanomedicine 12:759-70
Chandler, Joshua D; Hu, Xin; Ko, Eun-Ju et al. (2016) Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice. Am J Physiol Regul Integr Comp Physiol 311:R906-R916
Quan, Fu-Shi; Lee, Young-Tae; Kim, Ki-Hye et al. (2016) Progress in developing virus-like particle influenza vaccines. Expert Rev Vaccines 15:1281-93
Kim, Ki-Hye; Lee, Young-Tae; Hwang, Hye Suk et al. (2015) Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells. PLoS One 10:e0139916
Lee, Yu-Na; Hwang, Hye Suk; Kim, Min-Chul et al. (2015) Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology 476:217-25
Lee, Yu-Na; Kim, Min-Chul; Lee, Young-Tae et al. (2015) Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins. PLoS One 10:e0137822

Showing the most recent 10 out of 48 publications